Risk-based quality management in 2026
Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials.
FDA AI Guidance 2025 Interactive Visualizer
Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios.
ICH E6(R3) Interactive Visualizer: GCP Explained Visually
Explore the evolution of Good Clinical Practice with an interactive ICH E6(R3) visualizer showing ethics, risk-based oversight, and modern GCP design.
EMA Clinical Trials Map Visualizer Explained
Explore how the EMA Clinical Trials Map visualizes trial activity across Europe to support recruitment planning and site strategy decisions.
Decentralized Clinical Trials Outlook in the USA
Interactive visualizer exploring patient distribution, oncology expertise, and broadband access to support understanding of decentralized trial feasibility in the USA.
AI-Driven Predictive Analytics in Risk-Based Monitoring
Discover how AI-driven predictive analytics is reshaping risk-based monitoring under ICH E6(R3), enabling earlier intervention and stronger oversight.
The Cost of Poor Quality in Clinical Trials & How to Avoid It
Protocol changes and preventable risks can delay trials and drive major costs. Learn why proactive quality planning and RBQM lead to more predictable outcomes.
Phase III Oncology: Targeted Risk-Based QA Case Study
How ADAMAS used AI-augmented RBQM analytics to strengthen oversight, focus QA effort, and improve inspection readiness in a global Phase III oncology study.
Site Readiness Under E6(R3)
Key expectations for site readiness under ICH E6(R3), including documentation, risk-based oversight, and digital data governance.
ICH E6(R3) Final Guideline: What You Need to Know
ICH E6(R3) is now adopted. Learn what changes for sponsors, CROs, and sites, including accountability, CtQ planning, proactive monitoring, and participant protection.
